Innospec (IOSP) | Financial Analysis & Statements
Innospec Inc. Small-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
455.6M
Gross Profit
127.4M
27.96%
Operating Income
47.1M
10.34%
Net Income
47.4M
10.40%
EPS (Diluted)
$1.91
Balance Sheet Metrics
Total Assets
1.8B
Total Liabilities
499.5M
Shareholders Equity
1.3B
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
94.5M
Free Cash Flow
40.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Innospec Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.8B | 1.8B | 1.9B | 2.0B | 1.5B |
| Cost of Goods Sold | 1.3B | 1.3B | 1.4B | 1.4B | 1.0B |
| Gross Profit | 492.4M | 542.9M | 591.1M | 586.7M | 434.9M |
| Gross Margin % | 27.7% | 29.4% | 30.3% | 29.9% | 29.3% |
| Operating Expenses | |||||
| Research & Development | 51.0M | 47.8M | 41.7M | 38.7M | 37.4M |
| Selling, General & Administrative | 285.1M | 314.0M | 387.8M | 360.7M | 267.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 336.1M | 361.8M | 429.5M | 399.4M | 304.6M |
| Operating Income | 156.3M | 181.1M | 161.6M | 187.3M | 130.3M |
| Operating Margin % | 8.8% | 9.8% | 8.3% | 9.5% | 8.8% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | 1.1M | 1.5M |
| Other Non-Operating Income | -27.4M | -149.2M | 10.5M | -1.6M | 5.6M |
| Pre-tax Income | 138.1M | 41.2M | 174.4M | 184.6M | 134.4M |
| Income Tax | 21.5M | 5.6M | 35.3M | 51.6M | 41.3M |
| Effective Tax Rate % | 15.6% | 13.6% | 20.2% | 28.0% | 30.7% |
| Net Income | 116.6M | 35.6M | 139.1M | 133.0M | 93.1M |
| Net Margin % | 6.6% | 1.9% | 7.1% | 6.8% | 6.3% |
| Key Metrics | |||||
| EBITDA | 225.0M | 378.5M | 197.3M | 233.8M | 172.8M |
| EPS (Basic) | $4.69 | $1.43 | $5.60 | $5.37 | $3.78 |
| EPS (Diluted) | $4.67 | $1.42 | $5.56 | $5.32 | $3.75 |
| Basic Shares Outstanding | 24880000 | 24932000 | 24851000 | 24787000 | 24647000 |
| Diluted Shares Outstanding | 24880000 | 24932000 | 24851000 | 24787000 | 24647000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Innospec Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 292.5M | 289.2M | 203.7M | 147.1M | 141.8M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 342.3M | 341.7M | 359.8M | 334.6M | 284.5M |
| Inventory | 329.3M | 301.0M | 300.1M | 373.1M | 277.6M |
| Other Current Assets | 7.3M | 600.0K | 600.0K | 400.0K | 400.0K |
| Total Current Assets | 1.0B | 956.6M | 885.7M | 872.6M | 728.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 561.6M | 484.4M | 463.2M | 422.8M | 406.9M |
| Goodwill | 865.7M | 830.4M | 855.9M | 762.6M | 786.1M |
| Intangible Assets | 67.7M | 65.4M | 57.3M | 45.0M | 57.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 22.3M | 13.3M | 16.6M | 13.0M | 11.4M |
| Total Non-Current Assets | 827.8M | 778.1M | 821.7M | 731.1M | 842.8M |
| Total Assets | 1.8B | 1.7B | 1.7B | 1.6B | 1.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 174.7M | 163.8M | 163.6M | 165.3M | 148.7M |
| Short-term Debt | 15.9M | 13.9M | 13.6M | 13.9M | 12.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 7.0M | - | 1.2M | - | - |
| Total Current Liabilities | 360.1M | 371.4M | 371.5M | 405.8M | 336.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 36.8M | 31.0M | 31.6M | 31.4M | 23.1M |
| Deferred Tax Liabilities | 19.1M | 23.5M | 33.5M | 26.2M | 60.8M |
| Other Non-Current Liabilities | 8.8M | 4.2M | 15.9M | 14.8M | 17.7M |
| Total Non-Current Liabilities | 139.4M | 147.2M | 186.3M | 157.5M | 201.3M |
| Total Liabilities | 499.5M | 518.6M | 557.8M | 563.3M | 537.9M |
| Equity | |||||
| Common Stock | 300.0K | 300.0K | 300.0K | 300.0K | 300.0K |
| Retained Earnings | 1.1B | 1.0B | 1.0B | 924.2M | 822.9M |
| Treasury Stock | 115.2M | 93.0M | 94.3M | 95.4M | 90.6M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.3B | 1.2B | 1.1B | 1.0B | 1.0B |
| Key Metrics | |||||
| Total Debt | 52.7M | 44.9M | 45.2M | 45.3M | 35.6M |
| Working Capital | 644.5M | 585.2M | 514.2M | 466.8M | 391.5M |
Balance Sheet Composition
Innospec Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 116.6M | 35.6M | 139.1M | 133.0M | 93.1M |
| Depreciation & Amortization | 43.6M | 43.5M | 39.3M | 40.1M | 42.7M |
| Stock-Based Compensation | 8.1M | 8.5M | 8.0M | 6.7M | 4.4M |
| Working Capital Changes | -28.4M | -22.4M | 50.7M | -104.1M | -41.4M |
| Operating Cash Flow | 113.8M | 29.3M | 240.7M | 70.2M | 105.2M |
| Investing Activities | |||||
| Capital Expenditures | 1.1M | 500.0K | 100.0K | 200.0K | 2.9M |
| Acquisitions | -700.0K | -200.0K | -34.7M | 0 | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | 400.0K | 300.0K | -34.6M | 200.0K | 2.9M |
| Financing Activities | |||||
| Share Repurchases | -23.9M | -700.0K | -1.1M | -5.9M | -800.0K |
| Dividends Paid | -42.4M | -38.8M | -35.1M | -31.7M | -28.8M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | 0 | 0 | -2.3M | -100.0K | -600.0K |
| Financing Cash Flow | -63.9M | -35.3M | -39.0M | -33.7M | -20.0M |
| Free Cash Flow | 62.8M | 122.2M | 130.1M | 39.4M | 54.1M |
| Net Change in Cash | 50.3M | -5.7M | 167.1M | 36.7M | 88.1M |
Cash Flow Trend
Innospec Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.05
Forward P/E
11.99
Price to Book
1.40
Price to Sales
1.05
PEG Ratio
-0.10
Profitability Ratios
Profit Margin
6.56%
Operating Margin
10.32%
Return on Equity
9.15%
Return on Assets
5.47%
Financial Health
Current Ratio
2.79
Debt to Equity
3.95
Beta
0.88
Per Share Data
EPS (TTM)
$4.67
Book Value per Share
$53.52
Revenue per Share
$71.46
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IOSP | 1.9B | 16.05 | 1.40 | 9.15% | 6.56% | 3.95 |
| Linde plc | 236.5B | 34.73 | 6.16 | 17.82% | 20.30% | 70.63 |
| Sherwin-Williams | 83.7B | 32.88 | 18.09 | 59.39% | 10.90% | 306.06 |
| Ecovyst | 1.5B | 275.00 | 2.55 | 0.96% | -9.83% | 71.59 |
| Stepan Company | 1.1B | 19.21 | 0.89 | 4.77% | 2.57% | 58.20 |
| Oil-Dri | 1.0B | 19.91 | 3.83 | 20.75% | 11.01% | 20.33 |
Financial data is updated regularly. All figures are in the company's reporting currency.






